Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Proteins and Peptides in Tears Indicate Eye Conditions

By LabMedica International staff writers
Posted on 30 Apr 2013
Diseases such as dry eye and blepharitis (inflammation of the eyelids) change the proportions of certain proteins in normal tears.

A new test to diagnose dry eye would be especially useful because it is currently diagnosed by interview backed up by tests, which are not particularly reproducible.

Tatiana Suarez from Bioftalmik (Derio, Spain) and colleagues in Spain undertook a proteomics study using 2D PAGE to identify any potential protein biomarkers before carrying out a detailed validation study of the candidate species.

One hundred and forty-four participants were enrolled in the study, comprising 63 with dry eye, 38 with MGD and 43 healthy controls. More...
Tears were collected from 44 patients using surgical sponges, 16 with each disease, and 12 controls. The abundant protein immunoglobulin A was removed by immunoaffinity chromatography in case it swamped the less abundant proteins.

The remaining proteins were separated by 2D electrophoresis (PAGE) and their positions on the gel were identified by staining with a fluorescent dye. A total of 130 protein spots were resolved and image analysis was conducted to pinpoint the proteins which had different abundances between the three groups and these were identified by mass spectrometry.

Before refining the panel of proteins to a more manageable number that retained the predictive capability, they were screened by enzyme-linked immuno sorbent assay (ELISA) to identify the most predictive ones. Two validations steps followed in which the proteins were collected by sponge or capillary. The best classification method was achieved with the Random Forest and Naïve Bayes machine learning techniques which were trained using one set of results and confirmed on the others.

A network analysis of the 15 discriminatory proteins revealed that nine of them were directly or indirectly related. The major biological processes in which they are involved include inflammatory response, stress response, immune response, and oxidative stress response.

The final discriminatory panel obtained after refinement of the model consisted of five proteins: S100A6, annexin A1, annexin A11, cystatin-S and phospholipase A2-activating protein. Together they were able to discriminate between dry eye and control patients with high sensitivity and specificity. They could also distinguish between the dry eye, MGD, and control groups with good accuracy. The results were independent of the tear collection method.

The team will examine the biomarkers in a clinical setting and possibly develop a test for dry eye and meibomian gland dysfunction.

Related Links:
Bioftalmik




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.